Answer · read September 2, 2026
Ten letters, read in full, and what each one actually says.
No. A warning letter is FDA objecting to what a company wrote, not to what it sells, and not one of the 10 letters carried by companies on this roster states any action that stopped a business trading. It is worth reading. It is not a verdict.
What this piece found
10 of the 54 companies in this roster carry one, and 9 of those have a published review here. The other one — Hims — is held in the roster without a published review, so it appears in this count and not in the table at the bottom.
How the count was produced
Every company in the roster was screened against FDA's full warning-letter index on September 2, 2026 — 3,677 letters, downloaded whole rather than searched, because FDA's own search parameter is accepted and ignored and returns every company as clean. Screening by brand name alone is worthless here: the term “Eden” returns a Swedish tobacco company and a seafood processor, and “ro” returns several hundred letters about produce importers. Each candidate was then opened and matched on the website FDA says it reviewed, or on the company's legal name plus its street address.
Two things, and both are about language. The first is a label: FDA says that where a compounded product is pictured with the telehealth company's own name on it, that name implies the company compounded the drug, and in every one of these cases it did not — a pharmacy did. The second is a claim: sentences like Same active ingredient in Ozempic and Wegovy
or FDA-approved meds.
, which FDA says imply an approval compounded products have never had.
FDA states the underlying position the same way in every letter: Compounded drug products are not FDA-approved.
That is the sentence to take away from this piece if you take away one. It is not a criticism of any company; it is the legal category the product sits in, and it is true of every compounded GLP-1 on this site whether or not the seller has a letter.
No. We read all 10 in full on September 2, 2026 and not one states an executed seizure, injunction, recall or shutdown. Every one carries the same forward-looking sentence about what may follow if the company does not respond within fifteen days. That sentence is a warning about a possible future, and reading it as a record of something that already happened is the single most common way these letters get misreported.
The distinction that matters
A warning letter says FDA thinks a company broke a rule and should fix it. An enforcement action — a seizure, an injunction, a consent decree — says a court or the agency has stopped something. The first is common and the second is rare, and only the second tells you a company cannot do business. Nothing in these ten letters is the second.
Because they are sweeps. 2 are dated June 8, 2026, 5 are dated February 20, 2026, and 3 are dated September 9, 2025. A company that received one on a sweep date was not singled out; it was one of a batch FDA reviewed in the same pass, and the review dates in the letters say so — they cluster in the months before each issue date.
That is worth knowing when you compare two companies. The absence of a letter can mean a company writes carefully. It can also mean nobody has looked at it yet.
Because we did not match on the brand name. 9 of the 10 letters name, in their own text, the exact website this roster reads its prices from — that is the strongest match available, and it leaves nothing to interpret. The other one — MEDVi — was matched on the legal entity plus the street address printed on the company's own pages, because the letter reviews a different top-level domain for the same business. Each review says which of the two happened.
Why this is stated at all
This network has published fabricated allegations before by matching a company that merely resembled a name. A hit in an index is a reason to open the letter, never a reason to write about it.
Exactly as it handles a company without one. The letter goes in the review, numbered, dated, with FDA's own words for the allegation and a note that no action halted the business. Nothing in the code that builds a board, chooses a comparison or places a link reads whether a letter exists: every list on this site orders by what a month costs, and the roster's own file carries the rule at the top of it.
One of the 10 companies here with a letter, Direct Meds, pays us a commission. It kept its place on every board it was already on, and its review carries its letter in the same words as everyone else's. A disclosure policy that bends for a paying company is not a policy.
One row per published review, with the sentence FDA lifted out of that company's own site. These are FDA's transcriptions of the companies' marketing, not our summaries of FDA's objection.
| Company | What it is | What FDA quoted from their site | Where we read it |
|---|---|---|---|
| Eden | Wording that implies FDA approval | FDA-licensed 503(a) outsourcing facilities | Eden's own site, quoted in warning letter 728279Read 2026-08-31 |
| Maximus | Clinically proven, clinically studied | Clinically studied ingredients. | Maximus' own site, quoted in warning letter 730095Read 2026-08-31 |
| Bliv | The label says they compounded it | identify “Bliv” on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not | FDA's allegation in warning letter 721479 — it quotes no marketing claimRead 2026-08-31 |
| GoodGirlRx | Wording that implies FDA approval | FDA-approved meds. | GoodGirlRX's own site, quoted in warning letter 721449Read 2026-08-31 |
| Levity | Same active ingredient as the brand | The same ingredient as Ozempic® + Wegovy® | Levity's own site, quoted in warning letter 717990Read 2026-09-02 |
| Measured | Same active ingredient as the brand | Same active ingredient in Ozempic and Wegovy | Measured's own site, quoted in warning letter 721454Read 2026-08-31 |
| MEDVi | Same active ingredient as the brand | Same active ingredient as Wegovy® and Ozempic®. | MEDVi's own site, quoted in warning letter 721455Read 2026-09-02 |
| Direct Meds | Same active ingredient as the brand | Compounded semaglutide contains the same active ingredient as branded semaglutide. | Direct Meds' own site, quoted in warning letter 716822Read 2026-08-31 |
| Zealthy | Same active ingredient as the brand | Semaglutide is the active ingredient in Wegovy and Ozempic. Semaglutide is often more cost effective for Zealthy members whose insurance deny coverage of brand name medication like Wegovy or who are uninsured. | Zealthy's own site, quoted in warning letter 716501Read 2026-08-31 |
| Company | Letter | Issued | FDA's category |
|---|---|---|---|
| Eden | 728279 | June 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| Maximus | 730095 | June 8, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| Bliv | 721479 | February 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| GoodGirlRx | 721449 | February 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| Levity | 717990 | February 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| Measured | 721454 | February 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| MEDVi | 721455 | February 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) |
| Direct Meds | 716822 | September 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) |
| HimsNo published review here | 716567 | September 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) |
| Zealthy | 716501 | September 9, 2025 | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) |
Every letter is on FDA's own website under its number. The full text of each allegation, the recipient address it was sent to, and the domain FDA says it reviewed are on each company's review under On the record. 53 reviews are published here; 9 of them carry a letter.
Some companies named here pay us a commission when a reader starts care through a marked link. The one marked link on this page is one of them, picked by rule and disclosed beside it. Nothing above is ordered by who pays — the letters are listed newest first and the claim table follows the roster's own order. Who pays us · how we review · every review.